Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on NovoCure (NVCR) and Pacira Pharmaceuticals (PCRX).
NovoCure (NVCR)
Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on NovoCure today. The company’s shares closed last Thursday at $123.74.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 26.7% and a 50.8% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
NovoCure has an analyst consensus of Moderate Buy, with a price target consensus of $120.50.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals (PCRX)
Needham analyst Serge Belanger maintained a Buy rating on Pacira Pharmaceuticals today and set a price target of $68.00. The company’s shares closed last Thursday at $52.97.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -0.9% and a 36.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Pacira Pharmaceuticals with a $67.30 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
